This Book >>

  • 510pp. Published March 2016
  • Scientific Research Publishing, Inc., USA.
  • Category: Medicine & Healthcare
  • ISBN: 978-1-61896-157-0
  • (Hardcover) USD 89.00
  • ISBN: 978-1-61896-156-3
  • (Paperback) USD 69.00
Authors/Editors Price: 40% off
Buy at: bookorder@scirp.org

Connect with SCIRP >>

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)
Home > Books > Advances in Cancer Immunotherapy
Advances in Cancer Immunotherapy
  • Description
  • Author(s) Information
The mechanism of cancer immunotherapy is the use of immune system to treat cancer. And the Immune system is the built-in host defense mechanism which can fight against infectious agents as well as cancer. Since in 1940s, the first protective immunity against cancer was convincingly demonstrated with syn-geneic animal models, last century’s dream was to effectively prevent and cure cancers by immunological means. Individualized cancer therapy is a central goal of cancer biologists. In past years, this dream has slowly but surely become a reality. Immunotherapy is a rational means to this end—because the immune system can recognize a virtually limitless number of antigens secondary to the biology of genetic recombination in B and T lymphocytes. The Understanding of the interaction between cancer and immune system provides insights into mechanisms that can be exploited to disinhibit anti-tumor immune responses. This book covers the first-hand data in the field of cancer immunotherapy re-search, introducing the research status, the newest development, problems and outlook of cancer immunotherapy. The book is suitable for clinical practitioners and scientists; medical and medicinal students; medicinal researchers and those with an interest in cancer immunotherapy. Suggestions and opinions from read-ers are welcome.
Components of the Book:
  • FRONT MATTER
  • Chapter 1
    Primer on Tumor Immunology and Cancer Immunotherapy
  • Chapter 2
    Cancer Immunotherapy: Are We There Yet?
  • Chapter 3
    Highlights and Summary of the 28th Annual Meeting of the Society for Immunotherapy of Cancer
  • Chapter 4
    Towards Efficient Cancer Immunotherapy: Advances in Developing Artificial Antigen-Presenting Cells
  • Chapter 5
    Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects
  • Chapter 6
    Chimeric Antigen Receptor-Engineered T Cells for Cancer Immunotherapy: Progress and Challenges Prospects
  • Chapter 7
    The Development of Immunomodulatory Monoclonal Antibodies as a New Therapeutic Modality for Cancer: The Bristol-Myers Squibb Experience
  • Chapter 8
    A2aR Antagonists: Next Generation Checkpoint Blockade for Cancer Immunotherapy
  • Chapter 9
    New Perspective on Targeting the Tumor Suppressor p53 Pathway in the Tumor Microenvironment to Enhance the Efficacy of Immunotherapy
  • Chapter 10
    Bridging Infectious Disease Vaccines with Cancer Immunotherapy: A Role for Targeted RNA based Immunotherapeutics
  • Chapter 11
    Enhancing the Discovery and Development of Immunotherapies for Cancer Using Quantitative and Systems Pharmacology: Interleukin-12 as a Case Study
  • Chapter 12
    Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy
  • Chapter 13
    Current status of Granulocyte-Macrophage Colony-Stimulating Factor in the Immunotherapy of Melanoma
  • Chapter 14
    Advances in Immunotherapy for Melanoma
  • Chapter 15
    Immunotherapy in Endometrial Cancer—An Evolving Therapeutic Paradigm
Readership: Students, academics, teachers and other people attending or interested in Cancer Immunotherapy.
comments powered by Disqus